VYGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Voyager Therapeutics Inc (VYGR) is not a strong buy for a beginner investor with a long-term strategy at this time. While the technical indicators show positive momentum, the overbought RSI and significant insider selling suggest caution. Additionally, the company's financial performance shows declining revenue, which raises concerns about its growth potential. Without clear positive catalysts or strong trading signals, holding off on investment is advisable until further clarity emerges.
The stock shows positive momentum with a MACD histogram of 0.0817 (above 0 and expanding positively). However, the RSI is 84.566, indicating an overbought condition. Moving averages are converging, and the stock is trading near resistance levels (R1: 4.108, R2: 4.349). The pre-market price of 4.26 is above R1, suggesting potential resistance around R2.
The MACD indicates positive momentum, and the stock is trading above key pivot levels. Gross margin remains strong at 100%.
The RSI indicates the stock is overbought, and there is no recent news or significant trading trends to support a bullish case.
In Q3 2025, revenue dropped to $13,365,000 (-45.73% YoY). Net income improved to -$27,892,000 (+208.40% YoY), and EPS increased to -0.47 (+193.75% YoY). Gross margin remains at 100%. Despite improvements in net income and EPS, the sharp decline in revenue raises concerns about the company's growth trajectory.
Morgan Stanley raised the price target to $39 from $25, maintaining an Equal Weight rating. The analyst notes potential benefits from the Space Superiority Executive Order but highlights uncertainty around tangible impacts. This suggests a cautious outlook despite the raised price target.
